Understanding the Market | TRANSTHERA-B rises over 60% again, accumulating nearly 10 times since entering the market, with Northbound capital increasing its position by over HKD 300 million in the past two days

TRANSTHERA-B rose over 60% in early trading, reaching a high of HKD 679.5, with a cumulative increase of nearly 10 times since its entry into the market. As of the time of writing, it is up 50.6%, priced at HKD 625.5, with a transaction volume of HKD 1.177 billion and a total market value that once exceeded HKD 250 billion. On the news front, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that TRANSTHERA has been added to the Hong Kong Stock Connect eligible list, effective from September 8. Data shows that after its inclusion, northbound funds have continuously increased their holdings in TRANSTHERA, with purchases of HKD 180 million and HKD 142 million on September 12 and September 15, respectively. Public information indicates that TRANSTHERA focuses on discovering and developing innovative small molecule therapies for tumors, inflammation, and cardiovascular metabolic diseases. As of June 30, 2025, the company's main pipeline includes six clinical-stage candidate products and multiple preclinical-stage candidate products. Notably, TRANSTHERA previously released its interim results, showing that the group did not generate any main business revenue in the first half of the year, with other income and gains declining from HKD 10.4 million in the first half of 2024 to HKD 3.6 million, a decrease of 65.1%. Additionally, the company's core product, TT-00420, has recently received multiple positive developments